Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company develops non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The Company�s lead product, an intranasal formulation of Dexmedetomidine (Dex), has completed a placebo controlled trial demonstrating effective pain relief. Its lead product candidate is Dex-IN, its intranasal formulation of Dex. The Company is evaluating multiple formulations of Dex to target a range of pain indications, including cancer pain in addition to post-operative pain. In addition to Dex, it has second alpha -2 agonist candidate under development, Fadolmidine (Fado).